There are currently 65 clinical trials in Webster, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Center for Clinical Studies, Center of Reproductive Medicine, Center for Clinical Studies, LTD. LLP and Tranquil Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 3 Clinical Study of AK112 for NSCLC Patients
NCT05184712
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Texas Oncology- Webster, Webster, Texas
Conditions: Non-Squamous Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
NCT06073119
Recruiting
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details include a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2024
Locations: Center for Clinical Studies, LTD, LLP Site Number : 8400013, Webster, Texas
Conditions: Psoriasis
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: LEO Pharma Investigational Site, Webster, Texas
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
NCT05369832
Recruiting
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Texas Digestive Disease Consultants - TDDC - PPDS, Webster, Texas
Conditions: Colitis, Ulcerative
Register for Updates
Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)
NCT05431270
Recruiting
This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT199 (an Anti-CD73 mAb) alone and in combination with a PD-1 inhibitor, in patients with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Tranquility Research, Webster, Texas
Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Tranquil Clinical Research, Webster, Texas
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Center For Clinical Studies, LTD. LLP - 451 N Texas Ave, Webster, Texas
Conditions: Plaque Psoriasis
Register for Updates
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Tranquility Research, Webster, Texas
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Space City Pain Specialists, Webster, Texas
Conditions: Chronic Pain
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2024
Locations: Akero Clinical Study Site, Webster, Texas
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992
Recruiting
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Tranquil Clinical Research, Webster, Texas
Conditions: Lumbar Degenerative Disc Disease
Register for Updates
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
NCT05552326
Recruiting
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Tranquil Research, Webster, Texas
Conditions: Severe Hypertriglyceridemia
Register for Updates